Please assess the completion status of the following clinical trial:

Trial Title: Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 25 years of age.~* In the opinion of the principal investigator, the study eye has PCV with active exudation and/or bleeding that may benefit from treatment with study medication.~* Diagnosis of PCV via ICG Angiography with evidence of active leakage, active bleeding or recent decreased in vision.~* Baseline visual acuity better than or equal to 20/200 using ETDRS~* Willing and able to comply with clinic visits and study-related procedures~* Provide signed informed consent~Exclusion Criteria:~* Any history of previous vitrectomy~* Previous cataract surgery within the preceding 2 months of Day 0~* Active infections conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye~* Presence of any condition that would jeopardize the patient's participation in this study~* Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval at the time of study entry~* For the Treatment-Naïve cohort: no prior anti-VEGF (Macugen, Avastin, Lucentis, Eylea) in the study eye~* For the Previous-Treated cohort: no prior anti-VEGF (Macugen, Avastin, Lucentis) in the study eye within 30 days or enrollment in this study~* For the Previous-Treated cohort: no prior Eylea in the study eye~* Known allergy to any component of the study drug~* Blood pressure \>180/119 (systolic above 180 or diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, the patient can be eligible.~* Major surgery within 28 days prior to randomization or major surgery planned within the next 12 months. Major surgery is defined as a surgical procedure that is more extensive than needle biopsy/aspiration placement of a central venous access device, removal/biopsy of a skin lesion, or placement of a peripheral venous catheter~* Myocardial infarction, other cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 6 months prior to randomization~* Systemic anti-VEGF or pro-VEGF treatment within 3 months prior to randomization~* Pregnant or breast-feeding women~* Simultaneous participation in another medical investigational trial~* Sexually active men\* or women of childbearing potential\*\* who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device \[IUD\]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly)

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Previously Treated (Type: ACTIVE_COMPARATOR): Patients that have previously received treatment for polypoidal choroidal vasculopathy.~Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for previously treated arm.
- Treatment-Naive (Type: ACTIVE_COMPARATOR): Patients that have not received treatment for polypoidal choroidal vasculopathy.~Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for treatment-naive arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).